Effective and safe examination of Luseogliflozin for patients with fatty liver merger type II diabetes mellitus - Effective and safe examination of Luseogliflozin for patients with fatty liver merger type II diabetes mellitus

akakinen Clinic0 个研究点目标入组 40 人开始时间: 2016年2月18日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)A diabetic except the type 2 2)The patient who corresponds to the taboo in the attached document of Luseogliflozin 3)The patient who is complicated with a serious renal damage 4)A patient with BMI less than 22kg/m2 5)Is the patients using Insulin, GLP-1 receptor agonist, SGLT2 inhibitor or Thiazolidine within eight weeks for observation period before initiation 6)Viral hepatitis (HBs antigen positive, HCV antibody positive), autoimmune hepatitis, the patients with primary biliary cirrhosis 7)Ascites, hepatic encephalopathy, the patients with the jaundice 8)The patients who put on strong magnetic substance and an electronic device including the body such as pacemakers 9)A pregnant woman, nursing mother, the patients who may be pregnant 10)The patients whom drinking that is the way the quantity of excessive alcohol goes is found in 11)By confirmation of the accumulation situation of intrahepatic iron by Chie Malle Coe T2*W1 of the MRI imaging, the evaluation of the intrahepatic fat ratio is clearly difficulty and the judged patient 12)The patients who, in addition, judged that study doctor attending was inadequate

发起方

akakinen Clinic